Matrix of correlation (Spearman correlation coefficients) between biomarkers in women with spontaneous abortions (case patients) and in control patients
. | Case patients . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | aCL G . | aCL M . | aPE G . | aPE M . | aβ2GPI G . | aβ2GPI M . | aAnV G . | aAnV M . | at-PA G . | at-PA M . | aTF G . | aTF M . | aTM G . | aTM M . | HCY . | |||||||||||||||
aCL G | — | 0.042 | 0.042 | 0.054 | 0.048 | 0.016 | 0.344 | 0.030 | 0.001 | 0.031 | 0.008 | 0.018 | 0.031 | 0.021 | 0.013 | |||||||||||||||
aCL M | 0.024 | — | 0.060 | 0.041 | 0.084 | 0.001 | 0.049 | 0.006 | 0.029 | 0.018 | 0.001 | 0.005 | 0.014 | 0.011 | 0.002 | |||||||||||||||
aPE G | 0.015 | 0.031 | — | 0.046 | 0.033 | 0.063 | 0.005 | 0.070 | 0.053 | 0.036 | 0.049 | 0.027 | 0.067 | 0.074 | 0.013 | |||||||||||||||
aPE M | 0.009 | 0.061 | 0.042 | — | 0.366 | 0.048 | 0.157 | 0.059 | 0.019 | 0.074 | 0.055 | 0.076 | 0.075 | 0.069 | 0.202 | |||||||||||||||
aβ2GPI G | 0.059 | 0.064 | 0.076 | 0.091 | — | 0.020 | 0.234 | 0.019 | 0.007 | 0.031 | 0.014 | 0.028 | 0.012 | 0.035 | 0.081 | |||||||||||||||
aβ2GPI M | 0.069 | 0.017 | 0.014 | 0.056 | 0.037 | — | 0.010 | 0.925 | 0.736 | 0.878 | 0.851 | 0.881 | 0.671 | 0.882 | 0.180 | |||||||||||||||
aAnV G | 0.002 | 0.021 | 0.018 | 0.044 | 0.033 | 0.094 | — | 0.002 | 0.058 | 0.003 | 0.003 | 0.003 | 0.036 | 0.007 | 0.024 | |||||||||||||||
aAnV M | 0.094 | 0.021 | 0.012 | 0.070 | 0.064 | 0.900 | 0.105 | — | 0.663 | 0.811 | 0.776 | 0.810 | 0.633 | 0.825 | 0.182 | |||||||||||||||
at-PA G | 0.003 | 0.046 | 0.018 | 0.051 | 0.061 | 0.929 | 0.048 | 0.739 | — | 0.643 | 0.637 | 0.660 | 0.488 | 0.657 | 0.151 | |||||||||||||||
at-PA M | 0.011 | 0.027 | 0.021 | 0.034 | 0.070 | 0.864 | 0.070 | 0.770 | 0.956 | — | 0.763 | 0.791 | 0.584 | 0.825 | 0.182 | |||||||||||||||
aTF G | 0.060 | 0.063 | 0.004 | 0.025 | 0.013 | 0.829 | 0.045 | 0.734 | 0.701 | 0.718 | — | 0.947 | 0.572 | 0.763 | 0.155 | |||||||||||||||
aTF M | 0.077 | 0.076 | 0.016 | 0.013 | 0.002 | 0.867 | 0.051 | 0.771 | 0.730 | 0.750 | 0.954 | — | 0.596 | 0.798 | 0.142 | |||||||||||||||
aTM G | 0.060 | 0.039 | 0.036 | 0.052 | 0.048 | 0.835 | 0.052 | 0.758 | 0.676 | 0.702 | 0.688 | 0.728 | — | 0.758 | 0.264 | |||||||||||||||
aTM M | 0.066 | 0.027 | 0.037 | 0.046 | 0.041 | 0.886 | 0.063 | 0.800 | 0.722 | 0.754 | 0.729 | 0.762 | 0.942 | — | 0.173 | |||||||||||||||
HCY | 0.020 | 0.010 | 0.026 | 0.002 | 0.011 | 0.047 | 0.002 | 0.055 | 0.024 | 0.030 | 0.017 | 0.055 | 0.028 | 0.026 | — | |||||||||||||||
Control patients |
. | Case patients . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | aCL G . | aCL M . | aPE G . | aPE M . | aβ2GPI G . | aβ2GPI M . | aAnV G . | aAnV M . | at-PA G . | at-PA M . | aTF G . | aTF M . | aTM G . | aTM M . | HCY . | |||||||||||||||
aCL G | — | 0.042 | 0.042 | 0.054 | 0.048 | 0.016 | 0.344 | 0.030 | 0.001 | 0.031 | 0.008 | 0.018 | 0.031 | 0.021 | 0.013 | |||||||||||||||
aCL M | 0.024 | — | 0.060 | 0.041 | 0.084 | 0.001 | 0.049 | 0.006 | 0.029 | 0.018 | 0.001 | 0.005 | 0.014 | 0.011 | 0.002 | |||||||||||||||
aPE G | 0.015 | 0.031 | — | 0.046 | 0.033 | 0.063 | 0.005 | 0.070 | 0.053 | 0.036 | 0.049 | 0.027 | 0.067 | 0.074 | 0.013 | |||||||||||||||
aPE M | 0.009 | 0.061 | 0.042 | — | 0.366 | 0.048 | 0.157 | 0.059 | 0.019 | 0.074 | 0.055 | 0.076 | 0.075 | 0.069 | 0.202 | |||||||||||||||
aβ2GPI G | 0.059 | 0.064 | 0.076 | 0.091 | — | 0.020 | 0.234 | 0.019 | 0.007 | 0.031 | 0.014 | 0.028 | 0.012 | 0.035 | 0.081 | |||||||||||||||
aβ2GPI M | 0.069 | 0.017 | 0.014 | 0.056 | 0.037 | — | 0.010 | 0.925 | 0.736 | 0.878 | 0.851 | 0.881 | 0.671 | 0.882 | 0.180 | |||||||||||||||
aAnV G | 0.002 | 0.021 | 0.018 | 0.044 | 0.033 | 0.094 | — | 0.002 | 0.058 | 0.003 | 0.003 | 0.003 | 0.036 | 0.007 | 0.024 | |||||||||||||||
aAnV M | 0.094 | 0.021 | 0.012 | 0.070 | 0.064 | 0.900 | 0.105 | — | 0.663 | 0.811 | 0.776 | 0.810 | 0.633 | 0.825 | 0.182 | |||||||||||||||
at-PA G | 0.003 | 0.046 | 0.018 | 0.051 | 0.061 | 0.929 | 0.048 | 0.739 | — | 0.643 | 0.637 | 0.660 | 0.488 | 0.657 | 0.151 | |||||||||||||||
at-PA M | 0.011 | 0.027 | 0.021 | 0.034 | 0.070 | 0.864 | 0.070 | 0.770 | 0.956 | — | 0.763 | 0.791 | 0.584 | 0.825 | 0.182 | |||||||||||||||
aTF G | 0.060 | 0.063 | 0.004 | 0.025 | 0.013 | 0.829 | 0.045 | 0.734 | 0.701 | 0.718 | — | 0.947 | 0.572 | 0.763 | 0.155 | |||||||||||||||
aTF M | 0.077 | 0.076 | 0.016 | 0.013 | 0.002 | 0.867 | 0.051 | 0.771 | 0.730 | 0.750 | 0.954 | — | 0.596 | 0.798 | 0.142 | |||||||||||||||
aTM G | 0.060 | 0.039 | 0.036 | 0.052 | 0.048 | 0.835 | 0.052 | 0.758 | 0.676 | 0.702 | 0.688 | 0.728 | — | 0.758 | 0.264 | |||||||||||||||
aTM M | 0.066 | 0.027 | 0.037 | 0.046 | 0.041 | 0.886 | 0.063 | 0.800 | 0.722 | 0.754 | 0.729 | 0.762 | 0.942 | — | 0.173 | |||||||||||||||
HCY | 0.020 | 0.010 | 0.026 | 0.002 | 0.011 | 0.047 | 0.002 | 0.055 | 0.024 | 0.030 | 0.017 | 0.055 | 0.028 | 0.026 | — | |||||||||||||||
Control patients |
aCL G indicates anticardiolipin IgG; aCL M, anticardiolipin IgM; aPE G, antiphosphatidylethanolamine IgG; aPE M, antiphosphatidylethanolamine IgM; aβ2GP1 G, anti-β2-glycoprotein I IgM; aβ2GP1 M, anti-β2-glycoprotein I IgM; aAnV G, anti-annexin V IgG; aAnV M, anti-annexin V IgM; at-PA G, antitissue-type plasminogen activator IgG; at-PA M, antitissue-type plasminogen activator IgM; aTF G, antitissue factor IgG; aTF M, antitissue factor IgM; aTM G: antithrombomodulin IgG; aTM M, antithrombomodulin IgM; HCY, homocysteine. Coefficients in bold correspond to correlations between the 6 biomarkers finally found to be independent predictors.